Colorectal cancer (CRC) is fourth most common cancer in men and third in women
worldwide. Developing a diagnostic panel of sensitive and specific biomarkers for the early …

Aim There is not sufficient evidence about whether stool DNA methylation tests allow
prioritizing patients to colonoscopy. Due to the COVID‐19 pandemic, there will be a wait‐list …

Background Previous studies showed that the assessment of promoter hypermethylation of
a limited number of genes in tumor biopsies may identify the majority of colorectal tumors …

Objectives Colorectal cancer (CRC) screening using stool samples is now in routine use
where tumor DNA methylation analysis for leading markers such as NDRG4 and SDC2 is an …

Background Prevention and early detection of colorectal cancer (CRC) is a global priority,
with many countries conducting population-based CRC screening programs. Although …

Colorectal cancer (CRC) arises from accumulated genetic and epigenetic alterations, which
provide the possibility to identify tumor-specific biomarkers by analyzing fecal DNA …

Background: DNA hypermethylation of CpG-rich promoters is an epigenetic hallmark of
carcinogenesis. Numerous methylation markers for colorectal cancer (CRC) have been …

Purpose Colonoscopy and the fecal immunochemical test (FIT) are currently the most widely
used screening modalities for colorectal cancer (CRC), however, both with their own …

Detection of colorectal cancer at an early stage may significantly decrease mortality from the
disease. The current screening test of colonoscopy is of high efficacy, but its acceptance in …

A large number of tumor-related methylated genes have been suggested to be of diagnostic
and prognostic values for CRC when analyzed in patients' stool samples; however, reported …